Regeneron's weight-loss drug helps patients on Wegovy preserve muscle. By Mariam E Sunny and Bhanvi Satija. June 2, 2025 4:24 PM UTC Updated June 2, 2025 The Regeneron Pharmaceuticals ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced on Monday that its experimental drug, when combined with Novo Nordisk’s popular obesity medication Wegovy, helped patients preserve up to ...

A court battle between Regeneron and Amgen is testing the legal limits of how far drugmakers can go in using patents to ...

Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

Summary. Regeneron is financially strong, with steady cash flow, shareholder returns, and a healthy balance sheet, trading at a fair valuation. Their weight loss drug, trevogrumab could be a game ...

In a striking new study, the anti-obesity drug tirzepatide, known as Mounjaro and Zepbound, not only triggered significant ...

Regeneron highlighted that about 35% of weight loss from semaglutide alone was due to lean mass loss, ... Sanofi Stock Falls After Uneven Smoker’s Lung Drug Data.

The drugs are already being investigated as treatments for certain muscle- or bone-related conditions, but Regeneron reasoned that they could also be used to proactively prevent muscle loss while ...

Regeneron Pharmaceuticals has signed a new licensing agreement with Hansoh Pharmaceuticals Group to develop and sell its weight loss therapy outside of China. The pharmaceutical company said ...

Former FDA chief Dr. David Kessler says the new weight-loss drugs are a powerful tool to fight obesity. But they come with pitfalls. Here's his tips for how to use them successfully.

In addition, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) revealed plans to license an experimental obesity drug from China’s Hansoh Pharmaceuticals in a deal valued up to $2.01 billion.